OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis $0.0068 0.00 (0.00%) As of 10/19/2026 12:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and Trends About Appili Therapeutics Stock (OTCMKTS:APLIF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Appili Therapeutics alerts:Sign Up Key Stats Today's Range$0.0068▼$0.006850-Day Range$0.0041▼$0.009452-Week Range$0.00▼$0.02Volume36,649 shsAverage Volume6,455 shsMarket Capitalization$900.09 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Appili Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing treatments for infectious diseases, with an emphasis on antimicrobial resistance and infections for which existing therapies may be inadequate. The company has pursued opportunities in both established and underserved markets, including products intended to address serious bacterial and fungal infections. Appili’s development portfolio has included ATI-2307, an investigational antifungal candidate being studied for difficult-to-treat fungal infections, and ATI-1701, an investigational vaccine candidate for tularemia. The company has also evaluated additional anti-infective products and formulations through licensing, development and commercialization partnerships. Founded in 2015 and headquartered in Halifax, Nova Scotia, Appili has conducted development and partnership activities in Canada, the United States and other international markets. Its programs have involved collaborations with government and industry organizations, reflecting the company’s strategy of advancing anti-infective therapies through a combination of internal development and external partnerships.AI Generated. May Contain Errors. Read More Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLIF Stock News HeadlinesAppili Therapeutics to Delist from TSX and Move Listing to NEXSeptember 29, 2026 | tipranks.comAppili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 ProgramJuly 3, 2026 | financialpost.comFThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 20 at 1:00 AM | Behind the Markets (Ad)Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 ProgramJuly 3, 2026 | globenewswire.comAppili Therapeutics Reports Fiscal Year 2026 Financial and Operational ResultsJune 26, 2026 | financialpost.comFAppili Therapeutics Reports Fiscal Year 2026 Financial and Operational ResultsJune 26, 2026 | globenewswire.comAppili Therapeutics to Exhibit at World Vaccine Congress WashingtonMarch 30, 2026 | financialpost.comFAppili Therapeutics to Exhibit at World Vaccine Congress WashingtonMarch 30, 2026 | globenewswire.comSee More Headlines APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed this year? Appili Therapeutics' stock was trading at $0.0148 at the start of the year. Since then, APLIF shares have decreased by 54.1% and is now trading at $0.0068. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.01) EPS for the quarter. How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/20/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:APLIF CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year Founded2015Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.07 million Net Margins-1,225.55% Pretax Margin-1,216.79% Return on EquityN/A Return on Assets-406.42% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$180 thousand Price / Sales5.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-0.08Miscellaneous Outstanding Shares132,366,000Free Float116,694,000Market Cap$900.09 thousand OptionableNot Optionable Beta0.14 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:APLIF) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
